The use and toxicity of steroids in the management of patients with brain metastases
- 618 Downloads
Goals of work
To document the use of steroids and frequency of their side effects in patients with brain metastases.
Patients and methods
A survey of oncologists who manage patients with brain metastases was conducted to document steroid prescribing practice in our institution. In addition, a retrospective chart review of 88 patients treated with whole brain radiotherapy (WBRT), identified through the Palliative Radiation Oncology Program database, was conducted for a 6-month period to documents steroid doses prescribed, tapering schedules, and steroid side effects.
Ninety percent of physicians responded to the survey. Forty-five percent routinely used dexamethasone 4 mg qid (16 mg/day). The others determined the dose of steroid according to the presence or absence of neurological symptoms. Sixty percent tapered the patient’s steroids over the 4 weeks following completion of WBRT. The most common side effects noted by physicians were: increased appetite or weight gain (46%), insomnia (24%), gastro-intestinal symptoms (20%). In the retrospective study, dexamethasone 4 mg qid was prescribed to 52% patients prior and during WBRT. Sixty-six percent of patients were instructed to taper dexamethasone after WBRT, but details were not provided. The most frequently documented steroid-related side effects were: increased appetite (32%), proximal muscle weakness (28%), and insomnia (21%).
There is considerable variation in the prescribing practices even within a single institution, with many patients receiving high dose of steroids for considerable periods of time and developing related side effects. Strategies to reduce the amount and length of steroids may result in improved therapeutic ratio; we are currently accruing onto such a trial.
KeywordsBrain metastases Dexamethasone Steroid use Whole-brain-radiation therapy
- 1.Bascuas M, Amares SG, Machuca Munoz MT, Bascuas Asta L (1985) Effect of dexamethasone at the level of cerebral metastases: evaluation by CT and nuclear medicine. Rev Esp Oncol 32:539–542Google Scholar
- 5.Cairncross JG, Posner JB (1983) The management of brain metastases. In: Walker MD (ed) Oncology of the nervous system. vol. 12. Springer, Verlag, pp 342–377Google Scholar
- 6.Galicich JH, French LA, Melby JC (1961) Use of dexamethasone in the treatment of cerebral edema associated with brain Tumors. Lancet 81:46Google Scholar
- 9.Lagerwaard FJ et al (1991) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795–803Google Scholar
- 10.Mackworth N (1992) Quality of life self-reports from 200 brain tumor patients: comparison with Karnofsky performance scores. J Neuro–Oncol 14:243–253Google Scholar
- 15.Sawaya R (2001) Consideration in the diagnosis and management of brain metastases. Oncol 15:1144–1154Google Scholar
- 16.Schiff D (2001) Single brain metastases: current treatment options. Neurol 3:89–99Google Scholar
- 18.Tikhtman AJ, Patchell RA (1994) Brain metastases. In: Morantz RA, Walsh JW (eds) Brain tumors. A comprehensive text. Marcel Dekker, New York, pp 553–566Google Scholar
- 19.Vecht Ch J, Hovestadt A (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors. Neurol 44:675–680Google Scholar